Andrea Golan Featured in INCBA CLE: Hemp 201 — FDA and the Marketing of CBD Products
Aug 11, 2021
VS associate attorney Andrea Golan joined a panel of colleagues for the INCBA CLE: "Hemp 201 — FDA and the Marketing of CBD Products: Will FDA Provide a Regulatory Pathway for CBD in 2021?" Learn more about the CLE topic and watch it anytime here.
About the CLE:
Since the 2018 Farm Bill came into effect at the beginning of 2019, the US Food and Drug Administration has restricted the marketing of hemp-derived products including CBD products on the grounds that 1) CBD ingestible products can not legally be on the market because “CBD” is already approved as a drug article in Epidiolex; 2) there is not adequate safety data to support CBD as an ingredient in ingestible products. In the meantime, there is no legislation pending in Congress that would remove these impediments and allow a regulatory pathway. At the same time, FDA has not enforced against CBD products except through Warning Letters triggered by marketing that veers into clear medical curative claims. With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50 states?